Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 27 March 2012
Vol. 5, Issue 217, p. ra24
[DOI: 10.1126/scisignal.2002739]


Editor's Summary

Insight into the Obesity and Cancer Connection
The activity of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) increases in response to nutrients. Using mice with increased mTORC1 signaling in the liver due to a liver-specific deficiency in an inhibitory component of the mTORC1 pathway, Menon et al. found that these mice spontaneously developed hepatocellular carcinoma, a frequently occurring and aggressive form of liver cancer that has few treatment options. Treating these mice with a pharmacological inhibitor of mTORC1 (rapamycin) before the appearance of tumors blocked the development of hepatocellular carcinoma, as well as the pathological changes that preceded tumor formation. mTORC1 signaling increases during obesity, a major risk factor for liver cancer; therefore, these results suggest a role for mTORC1 in linking environmental factors such as diet to the risk of developing certain types of cancers.

Citation: S. Menon, J. L. Yecies, H. H. Zhang, J. J. Howell, J. Nicholatos, E. Harputlugil, R. T. Bronson, D. J. Kwiatkowski, B. D. Manning, Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice. Sci. Signal. 5, ra24 (2012).

Read the Full Text

Hyperactivation of Mammalian Target of Rapamycin Complex 1 (mTORC1) Promotes Breast Cancer Progression through Enhancing Glucose Starvation-induced Autophagy and Akt Signaling.
Y. Chen, H. Wei, F. Liu, and J.-L. Guan (2014)
J. Biol. Chem. 289, 1164-1173
   Abstract »    Full Text »    PDF »
The mTOR pathway negatively controls ATM by up-regulating miRNAs.
C. Shen and P. J. Houghton (2013)
PNAS 110, 11869-11874
   Abstract »    Full Text »    PDF »
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
R. K. Kelley, H. S. Nimeiri, P. N. Munster, M. T. Vergo, Y. Huang, C.- M. Li, J. Hwang, M. F. Mulcahy, B. M. Yeh, P. Kuhn, et al. (2013)
Ann. Onc. 24, 1900-1907
   Abstract »    Full Text »    PDF »
Hypoxia-inducible factor 1a is a Tsc1-regulated survival factor in newborn neurons in tuberous sclerosis complex.
D. M. Feliciano, S. Zhang, J. L. Quon, and A. Bordey (2013)
Hum. Mol. Genet. 22, 1725-1734
   Abstract »    Full Text »    PDF »
Hypoxia induces a phase transition within a kinase signaling network in cancer cells.
W. Wei, Q. Shi, F. Remacle, L. Qin, D. B. Shackelford, Y. S. Shin, P. S. Mischel, R. D. Levine, and J. R. Heath (2013)
PNAS 110, E1352-E1360
   Abstract »    Full Text »    PDF »
Defective Autophagy and mTORC1 Signaling in Myotubularin Null Mice.
K. M. Fetalvero, Y. Yu, M. Goetschkes, G. Liang, R. A. Valdez, T. Gould, E. Triantafellow, S. Bergling, J. Loureiro, J. Eash, et al. (2013)
Mol. Cell. Biol. 33, 98-110
   Abstract »    Full Text »    PDF »
Liver autophagy: physiology and pathology.
M. Komatsu (2012)
J. Biochem. 152, 5-15
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882